ALS drug failures and why COYA 302 is different
ALS, which is also known as Lou Gehrig's Disease, is a rare neurological disease that affects motor neurons — the nerve cells ...
Economic Uncertainty Hits Lateral Moves Market for Corporate Lawyers
Canadian recruiters say in the wake of a burgeoning tariff war with the U.S., Canadian law firms are more hesitant to add ...
ALS News Today3d
Woolsey secures additional funding to advance ALS therapy Bravyl
Woolsey Pharmaceuticals has secured additional funds to continue advancing its ROCK inhibitor Bravyl (oral fasudil) for the ...
Denali Therapeutics Ends ALS Trial Extension, Analyst Stays Optimistic Despite Trial Setback
Denali Therapeutics' ALS drug DNL343 failed to show efficacy, leading to the discontinuation of the trial extension. Analysts now focus on its Hunter syndrome drug.
Fierce Biotech3d
Denali's ALS drug fails to redeem itself, missing key biomarker in trial extension
Denali Therapeutics’ amyotrophic lateral sclerosis (ALS) drug has racked up another clinical miss this year, leaving the ...
Tiziana: Foralumab Drug Development Presses On With Additional EAP Enrollment
Fully human intranasal foralumab shows promise in treating Secondary Progressive Multiple Sclerosis, Alzheimer's, and ALS.
Tiziana Life Sciences Files Investigational New Drug Application with FDA for ALS Phase 2 Clinical Trial
Ivor Elrifi, CEO of Tiziana Life Sciences, expressed enthusiasm about this milestone, stating, "We are excited to initiate this important clinical study with the support of the ALS Association grant.